In the specialized field of biochemical research, the study of synthetic sequences has opened doors to understanding complex cellular signaling pathways. As an enthusiast who follows the latest developments in molecular biology, I have spent considerable time reviewing literature regarding the emp 1 peptide. This compound, often discussed in the context of its role as a mimetic of erythropoietin, represents a fascinating intersection of structural biology and receptor interaction studies.
Understanding the Molecular Profile of EMP-1
When analyzing Erythropoietin-Mimetic Peptide 1 (EMP-1), it is essential to distinguish it from the endogenous glycoprotein. The structural uniqueness of this peptide lies in its consensus sequence (YXCXXGPXTWXCX Jul 21, 1986 — Signal Peptide Website ; signal peptide, 1, 27 ; chain, Erythropoietin, 28, 193 ; disulfide bond, 34, 188. P), which allows it to interact specifically EPO mimetic peptide-1 (Synonyms: EMP-1) with the erythropoietin receptor. Researchers have noted that EMP-1 functions as a homodimer, a critical configuration that facilitates the activation of the receptor's extracellular domain.
From a technical standpoint, the molecular weight of this substance is approximately 2093.39 Daltons. My observation of various laboratory reports indicates that this 1 sequence is a subject of significant interest due to its ability to compete with natural ligands. It is important to note that EPO mimetic peptide-1 (EMP1) has been studied for its effects on cell proliferation and its influence on the cell cycle, particularly in controlled *in vitro* environments.
Distinctions in Nomenclature: EMP-1 vs. Epithelial Membrane Protein 1
A common point of confusion in literature is the overlap in naming conventions. While some contexts refer to Epithelial membrane protein 1 (EMP1)—a protein encoded by the *EMP1* gene—this should not be conflated with the synthetic EPO mimetic peptide-1 (EMP-1). The former is a glycoprotein that is highly expressed in EPO/Erythropoietin, Human brain tumor cells and serves as a multifunctional regulator, whereas the latter is a synthetic metic peptide sequence designed for specific receptor-binding research. Clarifying this distinction is vital for anyone tracki Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell ng the specific properties of Epithelial membrane protein 1.
Scientific Observations and Research Applications
In experimental settings, the peptide EMP-1 restrains bone growth in specific animal models, a finding that highlights the diverse biological pathways One EPO mimetic peptide sequence, EMP1, was targeted and more than 25 derivatives of this sequence were evaluated for their ability to compete with [125I]EPO that can be modulated by small synthetic molecules. Furthermore, the Erythropoietin-Mimetic Peptide 17 (EMP17) is frequently discussed alongside EMP-1. EMP17 is another derivative that activates the receptor, and it is known that the two potentially reactive amines present in its structure—one at the N-terminus and one in the lysine side chain—are critical for its chemical st Exhibits correct molecular weight. Solubility: Soluble in water. Storage: Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before ability and labeling, such as with FITC for visualization.
Important Considerations for Research Integrity
For those interested in the history of these compounds, it is well-documented that Erythropoietin (EPO) mimetic peptide (EMP) was initially identified to explore the potential of non-proteinaceous agonists. While the research is robust, it is essential to empha Identification of a 13 amino acid peptide mimetic of - PubMed size that these compounds are strictly for laboratory and analytical use.
There has been discourse regarding the misuse of these substances, specifically that the linear form of EMP1 is a performance-enhancing doping agent prohibited in various sporting contexts. Furthermore, while EPO-5, a short synthetic peptide fragment, and similar sequences like EMP-1 are studied for their potential to stimulate erythroid colony formation, they are far removed from clinical applications. Scientific literature notes that while they can correct anemia in patients with pure red-cell aplasia in experimental or theoretical models involving anti-erythropoietin antibodies, these are highly co by L Kuai · 2000 · Cited by 12 — Erythropoietin (EPO) mimetic peptide (EMP) encoding sequence was inserted into the gene of plasminogen activator inhibitor-1 (PAI-1) between Ala348 and ntrolled investigative scenarios.
Summary of Key Entities
* EMP-1: A 20-amino acid synthetic peptide acting as an EPO receptor agonist.
* Erythropoietin: The primary hormone involved in red blood cell production.
* EMP1 (Gene): A regulator of cell-cell interactions, distinct from the synthetic peptide.
* Research Focus: Investigating binding affinity, homodimerization, and receptor activation.
Whether you are looking at the solubility profiles or the way plasma contains over 120 different proteins that interact within complex systems, the s EPO mimetic peptide-1 (1 and 10 μM) promots erythroid colony formation from human peripheral blood and murine bone marrow. EPO mimetic peptide tudy of these peptides requires a high degree of precision. The peptide must always be stored according to manufacturer guidelines—usually in a lyophilized state at 0–5°C—to ensure it exhibits correct molecular weight and structural integrity for any valid scientific inquiry. Always ensure that your research aligns with institutional guidelines and ethical standards regarding the use of bioactive synthetic compounds.